Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
ObjectiveIn this study, we assessed plasma biomarkers to identify cognitive impairment in Parkinson’s disease (PD) patients by applying ultra-sensitive immunomagnetic reduction-based immunoassay (IMR).MethodsThe study enrolled 60 PD patients and 28 age- and sex-matched normal controls. Complete cogn...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2020.00112/full |
id |
doaj-3c102b1b2bea4f0f825267cc59324028 |
---|---|
record_format |
Article |
spelling |
doaj-3c102b1b2bea4f0f825267cc593240282020-11-25T02:26:27ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652020-04-011210.3389/fnagi.2020.00112509774Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s DiseaseNai-Ching Chen0Hsiu-Ling Chen1Shau-Hsuan Li2Yen-Hsiang Chang3Meng-Hsiang Chen4Nai-Wen Tsai5Chiun-Chieh Yu6Shieh-Yueh Yang7Cheng-Hsien Lu8Wei-Che Lin9Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Oncology and Hematology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Nuclear Medicine, Chang Gung University College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanMagQu Co., Ltd., New Taipei City, TaiwanDepartment of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TaiwanObjectiveIn this study, we assessed plasma biomarkers to identify cognitive impairment in Parkinson’s disease (PD) patients by applying ultra-sensitive immunomagnetic reduction-based immunoassay (IMR).MethodsThe study enrolled 60 PD patients and 28 age- and sex-matched normal controls. Complete cognitive function assessments were performed on participants using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating. PD patients with an MMSE score of ≦26 were defined as having cognitive impairment. Meanwhile, a 99mTc-TRODAT-1 scan was performed and plasma levels of Aβ-40, Aβ-42, T-tau, and α-synuclein were evaluated using IMR, subsequent correlation analyses were then performed.ResultsCompared with normal adults, PD patients have higher plasma levels of α-synuclein and T-tau, and a lower level of Aβ-40 (p < 0.05). Plasma levels of α-synuclein (r = −0.323, p = 0.002), Aβ-40 (r = 0.276, p = 0.01), and T-tau (r = −0.322, p = 0.002) are significantly correlated with MMSE scores. The TRODAT scan results, including visual inspection and quantification, revealed significant correlations between Aβ-40 and PD. Multiple regression analysis showed that the plasma levels of Aβ-40 (OR = 0.921, 95% CI = 0.879–0.962), α-synuclein (OR = 3.016, 95% CI = 1.703–5.339), and T-tau (OR = 1.069, 95% CI = 1.026–1.115) were independently associated with PD patients with cognitive impairment. The cutoff values for predicting cognitive deficits in PD patients were 45.101 pg/ml of Aβ-40, (Area under curve (AUC) = 0.791), 0.389 pg/ml of α-synuclein, (AUC = 0.790), and 30.555 pg/ml of T-tau (AUC = 0.726).ConclusionPlasma levels of α-synuclein, Aβ-40, and T-tau are potential biomarkers to detect cognitive impairment in PD patients.https://www.frontiersin.org/article/10.3389/fnagi.2020.00112/fullParkinson’s diseaseimmunomagnetic reductionplasma biomarkerplasma Aβ-40Aβ-42T-tau |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nai-Ching Chen Hsiu-Ling Chen Shau-Hsuan Li Yen-Hsiang Chang Meng-Hsiang Chen Nai-Wen Tsai Chiun-Chieh Yu Shieh-Yueh Yang Cheng-Hsien Lu Wei-Che Lin |
spellingShingle |
Nai-Ching Chen Hsiu-Ling Chen Shau-Hsuan Li Yen-Hsiang Chang Meng-Hsiang Chen Nai-Wen Tsai Chiun-Chieh Yu Shieh-Yueh Yang Cheng-Hsien Lu Wei-Che Lin Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease Frontiers in Aging Neuroscience Parkinson’s disease immunomagnetic reduction plasma biomarker plasma Aβ-40 Aβ-42 T-tau |
author_facet |
Nai-Ching Chen Hsiu-Ling Chen Shau-Hsuan Li Yen-Hsiang Chang Meng-Hsiang Chen Nai-Wen Tsai Chiun-Chieh Yu Shieh-Yueh Yang Cheng-Hsien Lu Wei-Che Lin |
author_sort |
Nai-Ching Chen |
title |
Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease |
title_short |
Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease |
title_full |
Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease |
title_fullStr |
Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease |
title_full_unstemmed |
Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease |
title_sort |
plasma levels of α-synuclein, aβ-40 and t-tau as biomarkers to predict cognitive impairment in parkinson’s disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2020-04-01 |
description |
ObjectiveIn this study, we assessed plasma biomarkers to identify cognitive impairment in Parkinson’s disease (PD) patients by applying ultra-sensitive immunomagnetic reduction-based immunoassay (IMR).MethodsThe study enrolled 60 PD patients and 28 age- and sex-matched normal controls. Complete cognitive function assessments were performed on participants using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating. PD patients with an MMSE score of ≦26 were defined as having cognitive impairment. Meanwhile, a 99mTc-TRODAT-1 scan was performed and plasma levels of Aβ-40, Aβ-42, T-tau, and α-synuclein were evaluated using IMR, subsequent correlation analyses were then performed.ResultsCompared with normal adults, PD patients have higher plasma levels of α-synuclein and T-tau, and a lower level of Aβ-40 (p < 0.05). Plasma levels of α-synuclein (r = −0.323, p = 0.002), Aβ-40 (r = 0.276, p = 0.01), and T-tau (r = −0.322, p = 0.002) are significantly correlated with MMSE scores. The TRODAT scan results, including visual inspection and quantification, revealed significant correlations between Aβ-40 and PD. Multiple regression analysis showed that the plasma levels of Aβ-40 (OR = 0.921, 95% CI = 0.879–0.962), α-synuclein (OR = 3.016, 95% CI = 1.703–5.339), and T-tau (OR = 1.069, 95% CI = 1.026–1.115) were independently associated with PD patients with cognitive impairment. The cutoff values for predicting cognitive deficits in PD patients were 45.101 pg/ml of Aβ-40, (Area under curve (AUC) = 0.791), 0.389 pg/ml of α-synuclein, (AUC = 0.790), and 30.555 pg/ml of T-tau (AUC = 0.726).ConclusionPlasma levels of α-synuclein, Aβ-40, and T-tau are potential biomarkers to detect cognitive impairment in PD patients. |
topic |
Parkinson’s disease immunomagnetic reduction plasma biomarker plasma Aβ-40 Aβ-42 T-tau |
url |
https://www.frontiersin.org/article/10.3389/fnagi.2020.00112/full |
work_keys_str_mv |
AT naichingchen plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT hsiulingchen plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT shauhsuanli plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT yenhsiangchang plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT menghsiangchen plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT naiwentsai plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT chiunchiehyu plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT shiehyuehyang plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT chenghsienlu plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease AT weichelin plasmalevelsofasynucleinab40andttauasbiomarkerstopredictcognitiveimpairmentinparkinsonsdisease |
_version_ |
1724847007667847168 |